Premium
Long‐term outcomes in kidney transplant recipients with end‐stage kidney disease due to anti‐glomerular basement membrane disease
Author(s) -
Singh Tripti,
Kharadjian Talar B.,
Astor Brad C.,
Panzer Sarah E.
Publication year - 2021
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.14179
Subject(s) - medicine , kidney disease , kidney transplantation , malignancy , transplantation , end stage renal disease , nephropathy , disease , glomerulonephritis , biopsy , kidney , gastroenterology , diabetes mellitus , endocrinology
Abstract Anti‐glomerular basement membrane (GBM) disease causes rapidly progressive glomerulonephritis and end‐stage kidney disease (ESKD). Studies of post‐transplant outcomes in patients with ESKD due to anti‐GBM disease in the United States are lacking. To better characterize outcomes of transplant recipients with a history of anti‐GBM disease, we examined patient survival and graft survival among recipients with anti‐GBM disease compared with IgA nephropathy at a single center in the United States. We analyzed patient survival, graft survival, disease recurrence, and malignancy rates for kidney transplant recipients with ESKD due to biopsy‐proven anti‐GBM disease who underwent kidney transplantation at our center between 1994 and 2015. 26 patients with biopsy‐proven anti‐GBM disease and 314 patients with IgAN underwent kidney transplantation from 1994 to 2015. The incidence of graft loss was 6.2 per 100 person‐years for anti‐GBM disease, which was similar to IgAN (4.08 per 100 person‐years, p = .09). Patient mortality for anti‐GBM was 0.03 per 100 person‐years, similar to IgAN (0.02 per 100 person‐years, p = .12). Disease recurrence occurred in one of the 26 anti‐GBM patients. Four out of 26 patients (15%) developed malignancy, most commonly skin cancer. Long‐term graft and patient survival for patients with ESKD due to anti‐GBM was similar to IgAN after kidney transplantation.